2016
DOI: 10.1016/j.jaut.2016.02.010
|View full text |Cite
|
Sign up to set email alerts
|

Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

5
35
4
4

Year Published

2016
2016
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 65 publications
(48 citation statements)
references
References 10 publications
5
35
4
4
Order By: Relevance
“…As far as the clinical picture is concerned, all our patients experienced fever, frequently associated with both joint and skin involvement, mirroring data previously published [5, 6, 8, 27, 3841]. In fact, it has been reported that fever occurs in 60–100% of AOSD patients, typically with the highest temperatures occurring in the evening.…”
Section: Discussionsupporting
confidence: 88%
See 2 more Smart Citations
“…As far as the clinical picture is concerned, all our patients experienced fever, frequently associated with both joint and skin involvement, mirroring data previously published [5, 6, 8, 27, 3841]. In fact, it has been reported that fever occurs in 60–100% of AOSD patients, typically with the highest temperatures occurring in the evening.…”
Section: Discussionsupporting
confidence: 88%
“…Joint involvement is reported in 70–100% of these patients, mainly in wrists, knees, and ankles. At the onset of disease, arthritis may be mild and transient, sometimes evolving into a chronic destructive symmetrical polyarthritis with carpal ankylosis [5, 6, 8]. Further, 60–80% of AOSD patients experience a macular or maculopapular evanescent salmon-pink skin rash associated with the fever spiking [3841]; some patients, those with a usually more severe outcome, may experience this skin involvement for many weeks [7, 42].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…[5][6][7] Esta enfermedad puede tener curso monocíclico/autolimitado, recurrente o crónico y las formas recurrentes ocurren hasta en el 36% de los casos, presentando usualmente recaídas 18 meses después del episodio inicial. 8 El tratamiento de la ESA es empírico y proviene, principalmente, de información de series de casos retrospectivos. Las opciones terapéuticas incluyen: glucocorticoides (pilar fundamental de la terapia), antiinflamatorios no esteroideos, 9 ahorradores de esteroides (metotrexato, azatioprina) e inmunomoduladores -también llamados modificadores de la respuesta biológica-(anti-IL-1, anti-IL-6 y anti-TNF); el uso de estos últimos se ha descrito hasta en un 30% de los pacientes que no lograron remisión con fármacos de primera línea.…”
Section: Introductionunclassified
“…Las opciones terapéuticas incluyen: glucocorticoides (pilar fundamental de la terapia), antiinflamatorios no esteroideos, 9 ahorradores de esteroides (metotrexato, azatioprina) e inmunomoduladores -también llamados modificadores de la respuesta biológica-(anti-IL-1, anti-IL-6 y anti-TNF); el uso de estos últimos se ha descrito hasta en un 30% de los pacientes que no lograron remisión con fármacos de primera línea. 3,4,[8][9][10] El síndrome de activación de macrófago es la complicación más frecuente de la ESA (3.2-12.8%), seguido de miocarditis, pericarditis constrictiva, endocarditis, choque hemodinámico, síndrome de dificultad respiratoria, hemorragia alveolar, coagulación intravascular diseminada, microangiopatía trombótica y hepatitis fulminante. Respecto a los factores de riesgo para el desarrollo de estas complicaciones existe poca información.…”
Section: Introductionunclassified